Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis
Article Swipe
Heather J. Litman
,
Kristin M. Sheffield
,
Oksana Pugach
,
Mingyang Shan
,
Paul R. Lakin
,
Zhanglin Lin Cui
,
Sarah E. Curtis
,
Joseph A. Johnston
,
Leslie R. Harrold
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1002/pst.70020
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1002/pst.70020
Studies incorporating randomized controlled trial (RCT) controls with real‐world (RW) patients face concerns of selection bias and unmeasured confounding. To evaluate two methods (Match, Test‐then‐Pool [MTP] and Matching and Bias Adjustment [MBA]) to construct a hybrid control arm using concurrent RCT control patients and trial‐eligible RW patients from the CorEvitas Rheumatoid Arthritis (RA) Registry to replicate the treatment effect obtained from the original RCT. The measures considered estimate the effect of baricitinib on the proportion achieving 20% improvement in American College of Rheumatology response (ACR20) and change in disease activity (Clinical Disease Activity Index, CDAI) for patients with moderately to severely active rheumatoid arthritis. Patients included RCT treated ( n = 102), a 50% random sample of the RCT control ( n = 49), and trial‐eligible RW ( n = 359). MTP used optimal propensity score (PS) matching to replace half of the RCT control group with a comparable RW control group ( n = 49) and tested for differences between RCT and RW control outcomes before combining into the hybrid control arm for analysis. MBA leveraged 3 sets of optimal PS matches to identify a RW control group and adjusted for residual differences in outcomes between RCT and RW controls during analysis when creating the hybrid control arm. Optimal matching produced a matched RW cohort with satisfactory balance on the majority of key covariates compared to RCT participants. Using MTP, the odds ratio (OR) for ACR20 from covariate adjusted modeling was 4.71 (95% confidence interval [CI] 2.51, 9.15). Using MBA, ACR20 treatment effect from bias and covariate adjusted modeling was 4.76 (2.10, 10.81). For reference, the OR for the treatment difference of ACR20 for the trial‐eligible population was 3.81 (2.13, 6.95) and was 4.74 (2.32, 10.00) for the RCT population with 50% sample of controls. With MTP with covariate adjustment, the treatment effect of mean CDAI change was −8.96 (−12.58, −5.35). For MBA with bias and covariate adjustment, the treatment effect of mean CDAI change was −9.85 (−15.16, −5.02). In the original RCT, the mean CDAI change was −8.88 (−12.58, −5.18) and for the RCT population with 50% sample of controls, the mean CDAI change was −10.10 (−14.46, −5.74). With both hybrid control methods using the combination of well‐matched RWD and RCT control patients, we replicated the Phase IIb trial results. Trial Registration: Data were used from Eli Lilly and Company's clinical trial (NCT01185353) and the CorEvitas Rheumatoid Arthritis Registry (NCT01402661), both registered at clinicaltrials.gov
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/pst.70020
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020
- OA Status
- bronze
- References
- 32
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411224410
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411224410Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/pst.70020Digital Object Identifier
- Title
-
Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase
IIb Randomized Controlled Trial of Baricitinib for Rheumatoid ArthritisWork title - Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-06-10Full publication date if available
- Authors
-
Heather J. Litman, Kristin M. Sheffield, Oksana Pugach, Mingyang Shan, Paul R. Lakin, Zhanglin Lin Cui, Sarah E. Curtis, Joseph A. Johnston, Leslie R. HarroldList of authors in order
- Landing page
-
https://doi.org/10.1002/pst.70020Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020Direct OA link when available
- Concepts
-
Rheumatoid arthritis, Medicine, Randomized controlled trial, Phase (matter), Internal medicine, Chemistry, Organic chemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
32Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411224410 |
|---|---|
| doi | https://doi.org/10.1002/pst.70020 |
| ids.doi | https://doi.org/10.1002/pst.70020 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40493525 |
| ids.openalex | https://openalex.org/W4411224410 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D001172 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Arthritis, Rheumatoid |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D011687 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Purines |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D013449 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Sulfonamides |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D001384 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Azetidines |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D008297 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Male |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D005260 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Female |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008875 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Middle Aged |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D018501 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Antirheumatic Agents |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D011720 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Pyrazoles |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D015982 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Bias |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D016896 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Treatment Outcome |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000368 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Aged |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D012042 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Registries |
| mesh[14].qualifier_ui | Q000379 |
| mesh[14].descriptor_ui | D016032 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | methods |
| mesh[14].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[15].qualifier_ui | Q000379 |
| mesh[15].descriptor_ui | D017322 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | methods |
| mesh[15].descriptor_name | Clinical Trials, Phase II as Topic |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D006801 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Humans |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D001172 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Arthritis, Rheumatoid |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D011687 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Purines |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D013449 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Sulfonamides |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D001384 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Azetidines |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D008297 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Male |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D005260 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Female |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D008875 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Middle Aged |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D018501 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Antirheumatic Agents |
| mesh[25].qualifier_ui | Q000627 |
| mesh[25].descriptor_ui | D011720 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | therapeutic use |
| mesh[25].descriptor_name | Pyrazoles |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D015982 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Bias |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D016896 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Treatment Outcome |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000368 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Aged |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D012042 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Registries |
| mesh[30].qualifier_ui | Q000379 |
| mesh[30].descriptor_ui | D016032 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | methods |
| mesh[30].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[31].qualifier_ui | Q000379 |
| mesh[31].descriptor_ui | D017322 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | methods |
| mesh[31].descriptor_name | Clinical Trials, Phase II as Topic |
| type | article |
| title | Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase |
| biblio.issue | 4 |
| biblio.volume | 24 |
| biblio.last_page | e70020 |
| biblio.first_page | e70020 |
| grants[0].funder | https://openalex.org/F4320307758 |
| grants[0].award_id | |
| grants[0].funder_display_name | Eli Lilly and Company |
| topics[0].id | https://openalex.org/T11112 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9919999837875366 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2705 |
| topics[0].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[0].display_name | Viral Infections and Immunology Research |
| topics[1].id | https://openalex.org/T10200 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.986299991607666 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2745 |
| topics[1].subfield.display_name | Rheumatology |
| topics[1].display_name | Rheumatoid Arthritis Research and Therapies |
| topics[2].id | https://openalex.org/T10151 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9746999740600586 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2721 |
| topics[2].subfield.display_name | Hepatology |
| topics[2].display_name | Hepatitis C virus research |
| funders[0].id | https://openalex.org/F4320307758 |
| funders[0].ror | https://ror.org/01qat3289 |
| funders[0].display_name | Eli Lilly and Company |
| is_xpac | False |
| apc_list.value | 4430 |
| apc_list.currency | USD |
| apc_list.value_usd | 4430 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777575956 |
| concepts[0].level | 2 |
| concepts[0].score | 0.830005407333374 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q187255 |
| concepts[0].display_name | Rheumatoid arthritis |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.5892321467399597 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C168563851 |
| concepts[2].level | 2 |
| concepts[2].score | 0.573302149772644 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[2].display_name | Randomized controlled trial |
| concepts[3].id | https://openalex.org/C44280652 |
| concepts[3].level | 2 |
| concepts[3].score | 0.4743840992450714 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q104837 |
| concepts[3].display_name | Phase (matter) |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.3765241503715515 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C185592680 |
| concepts[5].level | 0 |
| concepts[5].score | 0.0 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[5].display_name | Chemistry |
| concepts[6].id | https://openalex.org/C178790620 |
| concepts[6].level | 1 |
| concepts[6].score | 0.0 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[6].display_name | Organic chemistry |
| keywords[0].id | https://openalex.org/keywords/rheumatoid-arthritis |
| keywords[0].score | 0.830005407333374 |
| keywords[0].display_name | Rheumatoid arthritis |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.5892321467399597 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[2].score | 0.573302149772644 |
| keywords[2].display_name | Randomized controlled trial |
| keywords[3].id | https://openalex.org/keywords/phase |
| keywords[3].score | 0.4743840992450714 |
| keywords[3].display_name | Phase (matter) |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.3765241503715515 |
| keywords[4].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1002/pst.70020 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S141766756 |
| locations[0].source.issn | 1539-1604, 1539-1612 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1539-1604 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Pharmaceutical Statistics |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Pharmaceutical Statistics |
| locations[0].landing_page_url | https://doi.org/10.1002/pst.70020 |
| locations[1].id | pmid:40493525 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Pharmaceutical statistics |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40493525 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5064025296 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3511-4078 |
| authorships[0].author.display_name | Heather J. Litman |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210129365 |
| authorships[0].affiliations[0].raw_affiliation_string | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210129365 |
| authorships[0].institutions[0].ror | https://ror.org/04a6c5752 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210129365 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Navitas Systems (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Heather J. Litman |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[1].author.id | https://openalex.org/A5043605449 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3940-1795 |
| authorships[1].author.display_name | Kristin M. Sheffield |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[1].affiliations[0].raw_affiliation_string | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[1].institutions[0].id | https://openalex.org/I168537998 |
| authorships[1].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Eli Lilly (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kristin M. Sheffield |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[2].author.id | https://openalex.org/A5085773863 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4299-8652 |
| authorships[2].author.display_name | Oksana Pugach |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210129365 |
| authorships[2].affiliations[0].raw_affiliation_string | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[2].institutions[0].id | https://openalex.org/I4210129365 |
| authorships[2].institutions[0].ror | https://ror.org/04a6c5752 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210129365 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Navitas Systems (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Oksana Pugach |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[3].author.id | https://openalex.org/A5035716528 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-7131-562X |
| authorships[3].author.display_name | Mingyang Shan |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[3].affiliations[0].raw_affiliation_string | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[3].institutions[0].id | https://openalex.org/I168537998 |
| authorships[3].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Eli Lilly (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mingyang Shan |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[4].author.id | https://openalex.org/A5032296525 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-9295-4829 |
| authorships[4].author.display_name | Paul R. Lakin |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210129365 |
| authorships[4].affiliations[0].raw_affiliation_string | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210129365 |
| authorships[4].institutions[0].ror | https://ror.org/04a6c5752 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210129365 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Navitas Systems (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Paul Lakin |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[5].author.id | https://openalex.org/A5086108457 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-7034-0946 |
| authorships[5].author.display_name | Zhanglin Lin Cui |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[5].affiliations[0].raw_affiliation_string | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[5].institutions[0].id | https://openalex.org/I168537998 |
| authorships[5].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Eli Lilly (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Zhanglin Lin Cui |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[6].author.id | https://openalex.org/A5103857669 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Sarah E. Curtis |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[6].affiliations[0].raw_affiliation_string | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[6].institutions[0].id | https://openalex.org/I168537998 |
| authorships[6].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Eli Lilly (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Sarah E. Curtis |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[7].author.id | https://openalex.org/A5015927873 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-3913-9256 |
| authorships[7].author.display_name | Joseph A. Johnston |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[7].affiliations[0].raw_affiliation_string | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[7].institutions[0].id | https://openalex.org/I168537998 |
| authorships[7].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Eli Lilly (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Joseph A. Johnston |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Eli Lilly and Company Indianapolis Indiana USA |
| authorships[8].author.id | https://openalex.org/A5079841694 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-0170-2747 |
| authorships[8].author.display_name | Leslie R. Harrold |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210129365 |
| authorships[8].affiliations[0].raw_affiliation_string | CorEvitas, LLC Waltham Massachusetts USA |
| authorships[8].institutions[0].id | https://openalex.org/I4210129365 |
| authorships[8].institutions[0].ror | https://ror.org/04a6c5752 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210129365 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Navitas Systems (United States) |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Leslie R. Harrold |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | CorEvitas, LLC Waltham Massachusetts USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-06-12T00:00:00 |
| display_name | Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11112 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9919999837875366 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2705 |
| primary_topic.subfield.display_name | Cardiology and Cardiovascular Medicine |
| primary_topic.display_name | Viral Infections and Immunology Research |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W1489783725 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1002/pst.70020 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S141766756 |
| best_oa_location.source.issn | 1539-1604, 1539-1612 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1539-1604 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Pharmaceutical Statistics |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Pharmaceutical Statistics |
| best_oa_location.landing_page_url | https://doi.org/10.1002/pst.70020 |
| primary_location.id | doi:10.1002/pst.70020 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S141766756 |
| primary_location.source.issn | 1539-1604, 1539-1612 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1539-1604 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Pharmaceutical Statistics |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pst.70020 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Pharmaceutical Statistics |
| primary_location.landing_page_url | https://doi.org/10.1002/pst.70020 |
| publication_date | 2025-06-10 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3012524460, https://openalex.org/W2983727442, https://openalex.org/W4366463781, https://openalex.org/W4376478864, https://openalex.org/W4213166393, https://openalex.org/W4366464024, https://openalex.org/W4220745676, https://openalex.org/W4300003117, https://openalex.org/W4321360204, https://openalex.org/W3159368171, https://openalex.org/W3022623176, https://openalex.org/W2972625246, https://openalex.org/W3012403290, https://openalex.org/W2086102241, https://openalex.org/W3122812581, https://openalex.org/W4382765634, https://openalex.org/W2123414080, https://openalex.org/W6633655033, https://openalex.org/W2100950823, https://openalex.org/W1974616955, https://openalex.org/W2161584352, https://openalex.org/W1989668639, https://openalex.org/W2126049444, https://openalex.org/W2030614017, https://openalex.org/W2118502261, https://openalex.org/W6633431865, https://openalex.org/W4383988388, https://openalex.org/W4323349809, https://openalex.org/W4313641043, https://openalex.org/W3195798356, https://openalex.org/W2150291618, https://openalex.org/W2058815839 |
| referenced_works_count | 32 |
| abstract_inverted_index.( | 109, 121, 128, 153 |
| abstract_inverted_index.3 | 178 |
| abstract_inverted_index.= | 111, 123, 130, 155 |
| abstract_inverted_index.a | 35, 113, 148, 186, 213 |
| abstract_inverted_index.n | 110, 122, 129, 154 |
| abstract_inverted_index.In | 331 |
| abstract_inverted_index.OR | 268 |
| abstract_inverted_index.PS | 182 |
| abstract_inverted_index.RW | 46, 127, 150, 164, 187, 200, 215 |
| abstract_inverted_index.To | 20 |
| abstract_inverted_index.at | 405 |
| abstract_inverted_index.in | 79, 88, 195 |
| abstract_inverted_index.of | 14, 71, 82, 117, 142, 180, 223, 273, 295, 305, 323, 351, 369 |
| abstract_inverted_index.on | 73, 220 |
| abstract_inverted_index.to | 33, 55, 100, 139, 184, 227 |
| abstract_inverted_index.we | 376 |
| abstract_inverted_index.20% | 77 |
| abstract_inverted_index.49) | 156 |
| abstract_inverted_index.50% | 114, 293, 349 |
| abstract_inverted_index.Eli | 389 |
| abstract_inverted_index.For | 265, 313 |
| abstract_inverted_index.IIb | 380 |
| abstract_inverted_index.MBA | 176, 314 |
| abstract_inverted_index.MTP | 132, 298 |
| abstract_inverted_index.RCT | 41, 107, 119, 144, 162, 198, 228, 290, 346, 373 |
| abstract_inverted_index.RWD | 371 |
| abstract_inverted_index.The | 65 |
| abstract_inverted_index.and | 17, 27, 29, 44, 86, 125, 157, 163, 190, 199, 257, 283, 317, 343, 372, 391, 396 |
| abstract_inverted_index.arm | 38, 173 |
| abstract_inverted_index.for | 96, 159, 174, 192, 236, 269, 275, 288, 344 |
| abstract_inverted_index.key | 224 |
| abstract_inverted_index.the | 49, 57, 62, 69, 74, 118, 143, 170, 206, 221, 232, 267, 270, 276, 289, 302, 320, 332, 335, 345, 353, 367, 378, 397 |
| abstract_inverted_index.two | 22 |
| abstract_inverted_index.was | 242, 261, 279, 284, 309, 327, 339, 357 |
| abstract_inverted_index.(95% | 244 |
| abstract_inverted_index.(OR) | 235 |
| abstract_inverted_index.(PS) | 137 |
| abstract_inverted_index.(RA) | 53 |
| abstract_inverted_index.(RW) | 10 |
| abstract_inverted_index.3.81 | 280 |
| abstract_inverted_index.4.71 | 243 |
| abstract_inverted_index.4.74 | 285 |
| abstract_inverted_index.4.76 | 262 |
| abstract_inverted_index.49), | 124 |
| abstract_inverted_index.Bias | 30 |
| abstract_inverted_index.CDAI | 307, 325, 337, 355 |
| abstract_inverted_index.Data | 385 |
| abstract_inverted_index.MBA, | 251 |
| abstract_inverted_index.MTP, | 231 |
| abstract_inverted_index.RCT, | 334 |
| abstract_inverted_index.RCT. | 64 |
| abstract_inverted_index.With | 297, 361 |
| abstract_inverted_index.[CI] | 247 |
| abstract_inverted_index.arm. | 209 |
| abstract_inverted_index.bias | 16, 256, 316 |
| abstract_inverted_index.both | 362, 403 |
| abstract_inverted_index.face | 12 |
| abstract_inverted_index.from | 48, 61, 238, 255, 388 |
| abstract_inverted_index.half | 141 |
| abstract_inverted_index.into | 169 |
| abstract_inverted_index.mean | 306, 324, 336, 354 |
| abstract_inverted_index.odds | 233 |
| abstract_inverted_index.sets | 179 |
| abstract_inverted_index.used | 133, 387 |
| abstract_inverted_index.were | 386 |
| abstract_inverted_index.when | 204 |
| abstract_inverted_index.with | 8, 98, 147, 217, 292, 299, 315, 348 |
| abstract_inverted_index.(RCT) | 6 |
| abstract_inverted_index.102), | 112 |
| abstract_inverted_index.2.51, | 248 |
| abstract_inverted_index.359). | 131 |
| abstract_inverted_index.6.95) | 282 |
| abstract_inverted_index.ACR20 | 237, 252, 274 |
| abstract_inverted_index.CDAI) | 95 |
| abstract_inverted_index.Lilly | 390 |
| abstract_inverted_index.Phase | 379 |
| abstract_inverted_index.Trial | 383 |
| abstract_inverted_index.Using | 230, 250 |
| abstract_inverted_index.[MTP] | 26 |
| abstract_inverted_index.group | 146, 152, 189 |
| abstract_inverted_index.ratio | 234 |
| abstract_inverted_index.score | 136 |
| abstract_inverted_index.trial | 5, 381, 394 |
| abstract_inverted_index.using | 39, 366 |
| abstract_inverted_index.(2.10, | 263 |
| abstract_inverted_index.(2.13, | 281 |
| abstract_inverted_index.(2.32, | 286 |
| abstract_inverted_index.10.00) | 287 |
| abstract_inverted_index.9.15). | 249 |
| abstract_inverted_index.Index, | 94 |
| abstract_inverted_index.[MBA]) | 32 |
| abstract_inverted_index.active | 102 |
| abstract_inverted_index.before | 167 |
| abstract_inverted_index.change | 87, 308, 326, 338, 356 |
| abstract_inverted_index.cohort | 216 |
| abstract_inverted_index.during | 202 |
| abstract_inverted_index.effect | 59, 70, 254, 304, 322 |
| abstract_inverted_index.hybrid | 36, 171, 207, 363 |
| abstract_inverted_index.random | 115 |
| abstract_inverted_index.sample | 116, 294, 350 |
| abstract_inverted_index.tested | 158 |
| abstract_inverted_index.(ACR20) | 85 |
| abstract_inverted_index.(Match, | 24 |
| abstract_inverted_index.10.81). | 264 |
| abstract_inverted_index.College | 81 |
| abstract_inverted_index.Disease | 92 |
| abstract_inverted_index.Optimal | 210 |
| abstract_inverted_index.Studies | 1 |
| abstract_inverted_index.balance | 219 |
| abstract_inverted_index.between | 161, 197 |
| abstract_inverted_index.control | 37, 42, 120, 145, 151, 165, 172, 188, 208, 364, 374 |
| abstract_inverted_index.disease | 89 |
| abstract_inverted_index.matched | 214 |
| abstract_inverted_index.matches | 183 |
| abstract_inverted_index.methods | 23, 365 |
| abstract_inverted_index.optimal | 134, 181 |
| abstract_inverted_index.replace | 140 |
| abstract_inverted_index.treated | 108 |
| abstract_inverted_index.−8.88 | 340 |
| abstract_inverted_index.−8.96 | 310 |
| abstract_inverted_index.−9.85 | 328 |
| abstract_inverted_index.ABSTRACT | 0 |
| abstract_inverted_index.Activity | 93 |
| abstract_inverted_index.American | 80 |
| abstract_inverted_index.Matching | 28 |
| abstract_inverted_index.Patients | 105 |
| abstract_inverted_index.Registry | 54, 401 |
| abstract_inverted_index.activity | 90 |
| abstract_inverted_index.adjusted | 191, 240, 259 |
| abstract_inverted_index.analysis | 203 |
| abstract_inverted_index.clinical | 393 |
| abstract_inverted_index.compared | 226 |
| abstract_inverted_index.concerns | 13 |
| abstract_inverted_index.controls | 7, 201 |
| abstract_inverted_index.creating | 205 |
| abstract_inverted_index.estimate | 68 |
| abstract_inverted_index.evaluate | 21 |
| abstract_inverted_index.identify | 185 |
| abstract_inverted_index.included | 106 |
| abstract_inverted_index.interval | 246 |
| abstract_inverted_index.majority | 222 |
| abstract_inverted_index.matching | 138, 211 |
| abstract_inverted_index.measures | 66 |
| abstract_inverted_index.modeling | 241, 260 |
| abstract_inverted_index.obtained | 60 |
| abstract_inverted_index.original | 63, 333 |
| abstract_inverted_index.outcomes | 166, 196 |
| abstract_inverted_index.patients | 11, 43, 47, 97 |
| abstract_inverted_index.produced | 212 |
| abstract_inverted_index.residual | 193 |
| abstract_inverted_index.response | 84 |
| abstract_inverted_index.results. | 382 |
| abstract_inverted_index.severely | 101 |
| abstract_inverted_index.−10.10 | 358 |
| abstract_inverted_index.−5.18) | 342 |
| abstract_inverted_index.(Clinical | 91 |
| abstract_inverted_index.Arthritis | 52, 400 |
| abstract_inverted_index.Company's | 392 |
| abstract_inverted_index.CorEvitas | 50, 398 |
| abstract_inverted_index.achieving | 76 |
| abstract_inverted_index.analysis. | 175 |
| abstract_inverted_index.combining | 168 |
| abstract_inverted_index.construct | 34 |
| abstract_inverted_index.controls, | 352 |
| abstract_inverted_index.controls. | 296 |
| abstract_inverted_index.covariate | 239, 258, 300, 318 |
| abstract_inverted_index.leveraged | 177 |
| abstract_inverted_index.patients, | 375 |
| abstract_inverted_index.replicate | 56 |
| abstract_inverted_index.selection | 15 |
| abstract_inverted_index.treatment | 58, 253, 271, 303, 321 |
| abstract_inverted_index.−5.02). | 330 |
| abstract_inverted_index.−5.35). | 312 |
| abstract_inverted_index.−5.74). | 360 |
| abstract_inverted_index.(−12.58, | 311, 341 |
| abstract_inverted_index.(−14.46, | 359 |
| abstract_inverted_index.(−15.16, | 329 |
| abstract_inverted_index.Adjustment | 31 |
| abstract_inverted_index.Rheumatoid | 51, 399 |
| abstract_inverted_index.arthritis. | 104 |
| abstract_inverted_index.comparable | 149 |
| abstract_inverted_index.concurrent | 40 |
| abstract_inverted_index.confidence | 245 |
| abstract_inverted_index.considered | 67 |
| abstract_inverted_index.controlled | 4 |
| abstract_inverted_index.covariates | 225 |
| abstract_inverted_index.difference | 272 |
| abstract_inverted_index.moderately | 99 |
| abstract_inverted_index.population | 278, 291, 347 |
| abstract_inverted_index.propensity | 135 |
| abstract_inverted_index.proportion | 75 |
| abstract_inverted_index.randomized | 3 |
| abstract_inverted_index.reference, | 266 |
| abstract_inverted_index.registered | 404 |
| abstract_inverted_index.replicated | 377 |
| abstract_inverted_index.rheumatoid | 103 |
| abstract_inverted_index.unmeasured | 18 |
| abstract_inverted_index.adjustment, | 301, 319 |
| abstract_inverted_index.baricitinib | 72 |
| abstract_inverted_index.combination | 368 |
| abstract_inverted_index.differences | 160, 194 |
| abstract_inverted_index.improvement | 78 |
| abstract_inverted_index.Rheumatology | 83 |
| abstract_inverted_index.confounding. | 19 |
| abstract_inverted_index.real‐world | 9 |
| abstract_inverted_index.satisfactory | 218 |
| abstract_inverted_index.(NCT01185353) | 395 |
| abstract_inverted_index.Registration: | 384 |
| abstract_inverted_index.incorporating | 2 |
| abstract_inverted_index.participants. | 229 |
| abstract_inverted_index.(NCT01402661), | 402 |
| abstract_inverted_index.well‐matched | 370 |
| abstract_inverted_index.trial‐eligible | 45, 126, 277 |
| abstract_inverted_index.Test‐then‐Pool | 25 |
| abstract_inverted_index.clinicaltrials.gov | 406 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| citation_normalized_percentile.value | 0.35361271 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |